Compare BridgeBio Pharma Inc (BBIO) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Morgan Stanley — how do they compare? BridgeBio Pharma Inc trades at $65.7 (market cap $13.02B), while Morgan Stanley trades at $192.87 (market cap $304.12B). The key difference: Morgan Stanley is far larger — about 23.4× BridgeBio Pharma Inc's market cap, and Morgan Stanley pays a 2.38% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold BridgeBio Pharma Inc for 63 Days and Morgan Stanley for 95 Days on average.
| BBIO | MS | |
|---|---|---|
Market Cap | $13.02B | $304.12B |
Volume | 2,931,730 | 4,354,933 |
Sector | Health | Financials |
52-Week High | $90.17 | $228.42 |
52-Week Low | $51.94 | $151.86 |
Typical Hold Time | 63 Days | 95 Days |
Enterprise Value | $14.80B | $669.91B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $66.00, up 0.66% with a bearish technical signal despite strong analyst support. The company shows impressive revenue growth from $78M in 2022 to $502M in 2025, though it remains unprofitable with a -97.03% net income margin. Recent news highlights four global therapy launches planned by 2027, with Attruby nearing blockbuster status and positive clinical data for acoramidis in ATTR-CM.
While analyst consensus is strongly bullish (88.9% buy ratings, $110.09 target), investors face significant execution risk as the company burns cash (-$111M net flow in 2025) and carries substantial debt ($1.72B). The stock offers substantial upside if commercialization succeeds but requires tolerance for biotech volatility and prolonged losses.
Morgan Stanley (MS) trades at $196.31, down slightly by 0.02% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 15.64, net income margin of 27.59%, and robust revenue growth from $66.0B in 2025 to a projected $73.1B in 2026. Positive sentiment is driven by analyst optimism, with a consensus price target of $235.25 and 55.77% buy ratings, while news highlights growth in wealth management and AI financing.
The outlook for MS is favorable, supported by earnings momentum and strategic initiatives in AI and capital markets. Key risks include volatile cash flows from operations and rising debt-to-asset ratios. Investors should weigh the strong analyst support against macroeconomic and execution challenges for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
